In HIV-1, bictegravir-lenacapavir was noninferior to continued complex regimens for maintaining viral suppression at 48 wk. Millard PS. Ann Intern Med 2026 Jul 7. doi: 10.7326/ANNALS-26-02075.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Millard PS. In HIV-1, bictegravir-lenacapavir was noninferior to continued complex regimens for maintaining viral suppression at 48 wk. Ann Intern Med 2026 Jul 7. doi: 10.7326/ANNALS-26-02075.
PMID: 42407071